Funding Agency: Forest
Study Summary: This study investigates whether milnacipran, an FDA approved drug for the treatment of fibromyalgia, will reduce widespread, non-joint pain and pain sensitivity in patients with rheumatoid arthritis. This is a cross-over trial where patients will be on both milnacipran and placebo for 6 weeks with a 3-week wash-out period between treatment arms.
Patient Criteria: Men or women with stable RA that are at least 24 years old (stable doses of rheumatoid medication); have chronic widespread pain; not on narcotic pain medication such as Tylenol #3, Vicodin, Oxycontin, and oxycodone; no history of severe depression or suicidal ideation
Visit Summary: 5 visits over 16 weeks. One screen visit. First study visit (1-4 weeks after screen visit), 2nd study visit (6 weeks after visit 1), 3rd study visit (3 weeks after visit 2), final visit (6 weeks after visit 3).
Patient Remuneration: $40 per visit and a parking sticker.
This page was last modified on 10/3/2016